FEV1 · Adults (aged 40 or over) with COPD presenting with 1 or more exacerbations in the previous year. The 2 larger studies (Albert 2011; Sethi…
1 finding from 1 review
Treatment failure within 4 weeks ‐ current drugs only · exacerbations of COPD
Antibiotics may leads to lower treatment failure within 4 weeks ‐ current drugs only compared with placebo (low certainty).
1 finding from 1 review
Adverse events (timing not specified) · exacerbations of COPD
Antibiotics showed no clear difference in adverse events ‐ overall (any adverse events not specified) compared with placebo overall (moderate certainty).
1 finding from 1 review
All‐cause mortality · exacerbations of COPD
Antibiotics showed no clear difference in all‐cause mortality compared with placebo (low certainty).
1 finding from 1 review
Treatment failure within 4 weeks ‐ current drugs only ‐ inpatient · exacerbations of COPD
Antibiotics showed no clear difference in treatment failure within 4 weeks ‐ current drugs only ‐ inpatient compared with placebo (moderate certainty).
1 finding from 1 review
Treatment failure within 4 weeks ‐ drugs not currently used ‐ ICU · exacerbations of COPD
Antibiotics probably leads to lower treatment failure within 4 weeks ‐ drugs not currently used ‐ ICU compared with placebo (moderate certainty).
1 finding from 1 review
Length of stay (inpatients only) · exacerbations of COPD
1 finding from 1 review
Duration of hospital stay (days) ‐ ICU patients · exacerbations of COPD
1 finding from 1 review
Inpatient mortality · exacerbations of COPD
Antibiotics showed no clear difference in all‐cause mortality ‐ inpatients compared with placebo (moderate certainty).
1 finding from 1 review
ICU mortality · exacerbations of COPD
Antibiotics probably leads to lower all‐cause mortality ‐ ICU patients compared with placebo (moderate certainty).
1 finding from 1 review
Diarrhoea · exacerbations of COPD
Antibiotics showed no clear difference in adverse events ‐ diarrhoea compared with placebo overall (moderate certainty).
1 finding from 1 review
FVC (% predicted) Change from baseline · people with connective tissue disease‐associated interstitial lung disease
1 finding from 1 review
Change in lung function (diffusing capacity of the lung for carbon monoxide (DLCO) % predicted) · people with connective tissue disease‐associated interstitial lung disease
1 finding from 1 review
Adverse events ‐ pneumonia · people with connective tissue disease‐associated interstitial lung disease
Cyclophosphamide showed no clear difference in adverse events: pneumonia 12‐month compared with placebo (low certainty).
1 finding from 1 review
Adverse events: haematuria 12‐month · people with connective tissue disease‐associated interstitial lung disease
Cyclophosphamide may leads to higher adverse events: haematuria 12‐month compared with placebo (low certainty).
1 finding from 1 review
Health‐related quality of life (HAQ‐DI) · people with connective tissue disease‐associated interstitial lung disease
1 finding from 1 review
All‐cause mortality 12‐month · people with connective tissue disease‐associated interstitial lung disease
Cyclophosphamide showed no clear difference in all‐cause mortality 12‐month compared with placebo (low certainty).
1 finding from 1 review
Exacerbations requiring steroids or antibiotics or both: number of participants · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol showed no clear difference in exacerbations requiring steroids or antibiotics or both: number of… compared with placebo (moderate certainty).
1 finding from 1 review
Quality of life: number of participants with clinically significant improvement (≥ 4 units) in SGRQ total score · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol leads to higher quality of life: number of participants with clinically significant… compared with placebo (high certainty).
1 finding from 1 review
Non‐fatal serious adverse events · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol showed no clear difference in non‐fatal serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review